Facilitating
access
to deuterated and tritiated complex molecules
is of paramount importance due to the fundamental role of isotopically
labeled compounds in drug discovery and development. Deuterated analogues
of drugs are extensively used as internal standards for quantification
purposes or as active pharmaceutical ingredients, whereas tritiated
drugs are essential for preclinical ADME studies. In this report,
we describe the labeling of prevalent substructures in FDA-approved
drugs such as azines, indoles, alkylamine moieties, or benzylic carbons
by the in situ generation of Rh nanoparticles able to catalyze both
C(sp
2
)–H and C(sp
3
)–H activation
processes. In this easy-to-implement labeling process, Rh nanocatalysts
are formed by decomposition of a commercially available rhodium dimer
under a deuterium or tritium gas atmosphere (1 bar or less), using
the substrate itself as a surface ligand to control the aggregation
state of the resulting metallic clusters. It is noteworthy that the
size of the nanoparticles observed is surprisingly independent of
the substrate used and is homogeneous, as evidenced by transmission
electron microscopy experiments. This method has been successfully
applied to the one-step synthesis of (1) deuterated pharmaceuticals
usable as internal standards for MS quantification and (2) tritiated
drug analogues with very high molar activities (up to 113 Ci/mmol).